{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:48:32Z","timestamp":1784252912690,"version":"3.55.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100015979","name":"Pelotonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015979","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001582","name":"Dermatology Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00520-023-08160-0","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T05:01:35Z","timestamp":1700629295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Retrospective cohort study of CDK4\/6-inhibitor-induced alopecia in breast cancer patients"],"prefix":"10.1007","volume":"31","author":[{"given":"Abena","family":"Minta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Rose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candice","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneswari","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeti","family":"Sudheendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar","family":"Sardesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles L.","family":"Loprinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Ruddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Cathcart-Rake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"Dulmage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"issue":"6","key":"8160_CR1","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/0284186X.2020.1738547","volume":"59","author":"D Eiger","year":"2020","unstructured":"Eiger D, Wagner M, Pond\u00e9 NF, Nogueira MS et al (2020) The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). Acta Oncol 59(6):723\u2013725","journal-title":"Acta Oncol"},{"key":"8160_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2147\/PPA.S298670","volume":"15","author":"K Beusterien","year":"2021","unstructured":"Beusterien K, Maculaitis MC, Hallissey B et al (2021) Patient, oncologist, and payer preferences for adjuvant endocrine therapy and CDK4\/6 inhibitor regimens in early-stage breast cancer: a discrete choice experiment. Patient Prefer Adherence 15:611\u2013623. https:\/\/doi.org\/10.2147\/PPA.S298670","journal-title":"Patient Prefer Adherence"},{"issue":"10","key":"8160_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","volume":"18","author":"V Saggar","year":"2013","unstructured":"Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126\u20131134. https:\/\/doi.org\/10.1634\/theoncologist.2013-0193","journal-title":"Oncologist"},{"issue":"7","key":"8160_CR4","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40264-021-01071-1","volume":"44","author":"M Silvestri","year":"2021","unstructured":"Silvestri M, Cristaudo A, Morrone A et al (2021) Emerging skin toxicities in patients with breast cancer treated with new cyclin-dependent kinase 4\/6 inhibitors: a systematic review. Drug Saf 44(7):725\u2013732","journal-title":"Drug Saf"},{"issue":"15_suppl","key":"8160_CR5","doi-asserted-by":"publisher","first-page":"e 12537","DOI":"10.1200\/JCO.2019.37.15_suppl.e12537","volume":"37","author":"D Chan","year":"2019","unstructured":"Chan D, Freites Martinez AD, Goldfarb SB et al (2019) CDK4\/6 plus aromatase inhibitor-induced alopecia in breast cancer patients. J Clin Oncol 37(15_suppl):e 12537. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e12537","journal-title":"J Clin Oncol"},{"issue":"1","key":"8160_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","volume":"16","author":"RS Finn","year":"2015","unstructured":"Finn RS, Crown JP, Lang I et al (2015) The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study. Lancet Oncol 16(1):25\u201335","journal-title":"Lancet Oncol"},{"key":"8160_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I et al (2016) Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 17:425\u2013439","journal-title":"Lancet Oncol"},{"issue":"24","key":"8160_CR8","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S et al (2018) Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 36(24):2465\u20132472","journal-title":"J Clin Oncol"},{"issue":"7","key":"8160_CR9","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","volume":"19","author":"D Tripathy","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M et al (2018) Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 19(7):904\u2013915","journal-title":"Lancet Oncol"},{"issue":"25","key":"8160_CR10","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge","year":"2017","unstructured":"Sledge GW, Toi M, Neven P et al (2017) MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+\/HER2\u2212 advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875\u20132884","journal-title":"J Clin Oncol"},{"issue":"32","key":"8160_CR11","doi-asserted-by":"publisher","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","volume":"35","author":"MP Goetz","year":"2017","unstructured":"Goetz MP, Toi M, Campone M et al (2017) MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 35(32):3638\u20133646","journal-title":"J Clin Oncol"},{"issue":"1","key":"8160_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2006.12.029","volume":"57","author":"WS Lee","year":"2007","unstructured":"Lee WS, Ro BI, Hong SP, Bak H et al (2007) A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification. J Am Acad Dermatol 57(1):37\u201346","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"8160_CR13","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1001\/jamadermatol.2018.0454","volume":"154","author":"A Freites-Martinez","year":"2018","unstructured":"Freites-Martinez A, Shapiro J, Chan D et al (2018) Endocrine therapy-induced alopecia in patients with breast cancer. JAMA Dermatol 154(6):670\u2013675","journal-title":"JAMA Dermatol"},{"issue":"2","key":"8160_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-021-06169-9","volume":"188","author":"S Chawla","year":"2021","unstructured":"Chawla S, Hill A, Fearfield L, Johnston S, Parton M, Heelan K (2021) Cutaneous toxicities occurring during palbociclib (CDK4\/6 inhibitor) and endocrine therapy in patients with advanced breast cancer: a single-centre experience. Breast Cancer Res Treat 188(2):535\u2013545","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"8160_CR15","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s40257-021-00645-0","volume":"23","author":"E Raschi","year":"2022","unstructured":"Raschi E, Fusaroli M, La Placa M et al (2022) Skin toxicities with cyclin-dependent kinase 4\/6 inhibitors in breast cancer: signals from disproportionality analysis of the FDA adverse event reporting system. Am J Clin Dermatol 23(2):247\u2013255","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"8160_CR16","doi-asserted-by":"publisher","first-page":"3658","DOI":"10.3390\/cancers15143658","volume":"15","author":"P Sollena","year":"2023","unstructured":"Sollena P, Vasiliki N, Kotteas E, Stratigos AJ et al (2023) On behalf of the EADV Task Force Dermatology For Cancer Patients. Cyclin-dependent kinase 4\/6 inhibitors and dermatologic adverse events: results from the EADV task force \u201cDermatology for Cancer Patients\u201d International Study. Cancers (Basel) 15(14):3658","journal-title":"Cancers (Basel)"},{"key":"8160_CR17","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/jdv.16159","volume":"34","author":"DM Barrios","year":"2020","unstructured":"Barrios DM, Phillips GS, Freites-Martinez A et al (2020) Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study. J Eur Acad Dermatol Venereol 34:1340\u20131347","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"8160_CR18","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","volume":"80","author":"A Freites-Martinez","year":"2019","unstructured":"Freites-Martinez A, Shapiro J, Goldfarb S et al (2019) Hair disorders in patients with cancer. J Am Acad Dermatol 80(5):1179\u20131196","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"8160_CR19","first-page":"490","volume":"2","author":"A Rossi","year":"2021","unstructured":"Rossi A, Caro G, Magri F, Fortuna MC, Carlesimo M (2021) Clinical aspect, pathogenesis and therapy options of alopecia induced by hormonal therapy for breast cancer. Explor Target Antitumor Ther 2(5):490\u2013495","journal-title":"Explor Target Antitumor Ther"},{"issue":"5","key":"8160_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jaad.2022.12.005","volume":"88","author":"J Kang","year":"2023","unstructured":"Kang J, Lee JW, Kwon O (2023) Efficacy of low-dose oral minoxidil in the management of anticancer therapy-induced alopecia in patients with breast cancer: a retrospective cohort study. J Am Acad Dermatol 88(5):1170\u20131173","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"8160_CR21","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911031","volume":"11","author":"TS Purba","year":"2019","unstructured":"Purba TS, Ng\u2019andu K, Brunken L, Smart E, Mitchell E, Hassan N, O\u2019Brien A, Mellor C, Jackson J, Shahmalak A, Paus R (2019) CDK4\/6 inhibition mitigates stem cell damage in a novel model for taxane-induced alopecia. EMBO Mol Med 11(10):e11031","journal-title":"EMBO Mol Med"},{"issue":"5","key":"8160_CR22","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/14656566.2020.1721463","volume":"21","author":"K York","year":"2020","unstructured":"York K, Meah N, Bhoyrul B, Sinclair R (2020) A review of the treatment of male pattern hair loss. Expert Opin Pharmacother 21(5):603\u2013612","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"8160_CR23","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaad.2020.05.081","volume":"83","author":"C Wei","year":"2020","unstructured":"Wei C, Bovonratwet P, Gu A, Moawad G et al (2020) Spironolactone use does not increase the risk of female breast cancer recurrence: a retrospective analysis. J Am Acad Dermatol 83(4):1021\u20131027","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"8160_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-018-4996-3","volume":"174","author":"RN Rozner","year":"2019","unstructured":"Rozner RN, Freites-Martinez A, Shapiro J et al (2019) Safety of 5\u03b1-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies. Breast Cancer Res Treat 174(1):15\u201326","journal-title":"Breast Cancer Res Treat"},{"issue":"7","key":"8160_CR25","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1080\/09546634.2022.2109567","volume":"33","author":"Aditya K Gupta","year":"2022","unstructured":"Gupta Aditya K, Talukder Mesbah et al (2022) Comparison of oral minoxidil, finasteride, and dutasteride for treating androgenetic alopecia. J Dermatol Treat 33(7):2946\u20132962. https:\/\/doi.org\/10.1080\/09546634.2022.2109567","journal-title":"J Dermatol Treat"},{"issue":"16","key":"8160_CR26","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2147\/CCID.S398950.PMID:36923692;PMCID:PMC10010138","volume":"9","author":"C Wang","year":"2023","unstructured":"Wang C, Du Y, Bi L, Lin X, Zhao M, Fan W (2023) The efficacy and safety of oral and topical spironolactone in androgenetic alopecia treatment: a systematic review. Clin Cosmet Investig Dermatol 9(16):603\u2013612. https:\/\/doi.org\/10.2147\/CCID.S398950.PMID:36923692;PMCID:PMC10010138","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"8160_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14678","volume":"34","author":"H Abdel-Raouf","year":"2021","unstructured":"Abdel-Raouf H, Aly UF, Medhat W et al (2021) A novel topical combination of minoxidil and spironolactone for androgenetic alopecia: clinical, histopathological, and physicochemical study. Dermatol Ther 34(1):e14678","journal-title":"Dermatol Ther"},{"key":"8160_CR28","unstructured":"Souza A, Strober BE (2012) Chapter 214. Principles of topical therapy. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K (eds) Fitzpatrick's Dermatology in General Medicine, 8e. McGraw Hill. https:\/\/accessmedicine.mhmedical.com\/content.aspx?bookid=392&sectionid=41138950"},{"issue":"345","key":"8160_CR29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e4447","volume":"13","author":"IS Mackenzie","year":"2012","unstructured":"Mackenzie IS, Macdonald TM, Thompson A et al (2012) Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study. BMJ 13(345):e4447","journal-title":"BMJ"},{"issue":"1","key":"8160_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10549-022-06847-2","volume":"198","author":"A Alvarez","year":"2023","unstructured":"Alvarez A, Bernal AM, Anampa J (2023) Racial disparities in overall survival after the introduction of cyclin-dependent kinase 4\/6 inhibitors for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res Treat 198(1):75\u201388","journal-title":"Breast Cancer Res Treat"},{"key":"8160_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s10549-018-4901-0","volume":"172","author":"C Messina","year":"2018","unstructured":"Messina C, Cattrini C, Buzzatti G et al (2018) CDK4\/6 inhibitors in advanced hormone receptor-positive\/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat 172:9\u201321","journal-title":"Breast Cancer Res Treat"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-08160-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-08160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T14:11:47Z","timestamp":1703167907000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-08160-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["8160"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-08160-0","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"assertion":[{"value":"16 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ohio State University Institutional Review Board (IRB#2021H0264).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Loprinzi reports personal fees from PledPharma, personal fees from Disarm Therapeutics, personal fees from Asahi Kasei\/Veloxis, personal fees from Metys Pharmaceuticals, personal fees from OnQuality, personal fees from Mitsubishi Tanabe, personal fees from NKMax, personal fees from Novartis, personal fees from HengRui, personal fees from Nuro Bio, personal fees from Osmol Therapeutics, Inc., personal fees from Grunenthal, personal fees from Genentech, personal fees from Bexion, personal fees from Emmes Company, personal fees from Pfizer, and personal fees from Toray, all outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"717"}}